{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:14:05Z","timestamp":1791288845879,"version":"4.3.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Urachal cancer (UrC) is a rare, non-urothelial malignancy. Its natural history and management are poorly understood. Although localized to the bladder dome, the most common histological subtype of UrC is adenocarcinoma. UrC develops from an embryonic remnant, and is frequently diagnosed in advanced stage with poor prognosis. The treatment is not standardized, and based only on case reports and small series. This large retrospective multicentric study was conducted by the French Genito-Urinary Tumor Group to gain a better understanding of UrC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>data has been collected retrospectively on 97 patients treated at 22 French Cancer Centers between 1996 and 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow-up was 59 months (range 44-96). The median age at diagnosis was 53 years (range 20-86), 45% were females and 23% had tobacco exposure. For patients with localized disease (Mayo I-II, n=46) and with lymph-node invasion (Mayo III, n=13) median progression-free-survival (mPFS) was 31 months (95% CI: 20-67) and 7 months (95% CI: 6-not reached (NR)), and median overall survival (mOS) was 73 months (95% CI: 57-NR) and 22 months (95% CI: 21-NR) respectively. For 45 patients with Mayo I-III had secondary metastatic progression, and 20 patients were metastatic at diagnosis. Metastatic localization was peritoneal for 54% of patients. Most patients with localized tumor were treated with partial cystectomy, with mPFS of 20 months (95% CI: 14-49), and only 12 patients received adjuvant therapy. Metastatic patients (Mayo IV) had a mOS of 23 months (95% CI: 19-33) and 69% received a platin-fluorouracil combination treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>UrC is a rare tumor of the bladder where patients are younger with a higher number of females, and a lower tobacco exposure than in standard urothelial carcinoma. For localized tumor, partial cystectomy is recommended. The mOS and mPFS were low, notably for patients with lymph node invasion. For metastatic patients the prognosis is poor and standard therapy is not well-defined. Further clinical and biological knowledge are needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1110003","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T06:23:00Z","timestamp":1674109380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group"],"prefix":"10.3389","volume":"13","author":[{"given":"M.","family":"Guerin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Miran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Colomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cabart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pericart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Deleuze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Coquan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Laramas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Abbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mesnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Borchiellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Boughalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JL.","family":"Deville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cancel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Baciarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Flechon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"B1","first-page":"418\u201320","article-title":"Cancer colloide de la lombille et de paroi abdominale anterieure ayant envahi la vessie","volume":"6","author":"Hue","year":"1863","journal-title":"Union Med la Siene-Inf Rouen"},{"key":"B2","doi-asserted-by":"publisher","first-page":"218\u221221","DOI":"10.1016\/0090-4295(85)90112-8","article-title":"Urachal carcinoma","volume":"26","author":"Johnson","year":"1985","journal-title":"Urology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"659\u221268","DOI":"10.1097\/PAS.0b013e31819aa4ae","article-title":"Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation","volume":"33","author":"Gopalan","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"301\u22127","DOI":"10.1016\/j.jpp.2013.08.004","article-title":"Les Anomalies cong\u00e9nitales de l\u2019ouraque chez l\u2019enfant\u202f: le point de vue du chirurgien p\u00e9diatre","volume":"26","author":"El Azzouzi","year":"2013","journal-title":"J P\u00e9diatrie Pu\u00e9ricult"},{"key":"B5","doi-asserted-by":"publisher","first-page":"555\u221262","DOI":"10.1111\/j.1464-410X.1970.tb04503.x","article-title":"Carcinoma of the urachus","volume":"42","author":"Beck","year":"1970","journal-title":"Br J Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"721\u22128","DOI":"10.1002\/cncr.22059","article-title":"Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder","volume":"107","author":"Wright","year":"2006","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1\u22128","DOI":"10.1016\/S0022-5347(17)50167-6","article-title":"Malignant urachal lesions","volume":"131","author":"Sheldon","year":"1984","journal-title":"J Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1\u22126","DOI":"10.1016\/j.euros.2022.02.009","article-title":"Current management of urachal carcinoma: An evidence-based guide for clinical practice","volume":"39","author":"Loizzo","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"712\u221220","DOI":"10.1002\/cncr.22060","article-title":"Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy","volume":"107","author":"Ashley","year":"2006","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7308168","DOI":"10.1155\/2018\/7308168","article-title":"Biomarkers in urachal cancer and adenocarcinomas in the bladder: A comprehensive review supplemented by own data","volume":"2018","author":"Reis","year":"2018","journal-title":"Dis Markers"},{"key":"B11","doi-asserted-by":"publisher","first-page":"13\u221220","DOI":"10.1007\/s00428-018-2467-1","article-title":"Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis","volume":"474","author":"Riva","year":"2019","journal-title":"Virchows Arch Int J Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2042\u22127","DOI":"10.1016\/S0022-5347(06)00263-1","article-title":"Population based survival data on urachal tumors","volume":"175","author":"Pinthus","year":"2006","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683190","article-title":"The prognosis and oncological predictor of urachal carcinoma of the bladder: A Large scale multicenter cohort study analyzed 203 patients with long term follow-up","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol 31 mai"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4166\u221274","DOI":"10.1002\/cam4.3059","article-title":"Urachal carcinoma: Impact of recurrence pattern and lymphadenectomy on long-term outcomes","volume":"9","author":"Duan","year":"2020","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.927913","article-title":"Urachal carcinoma: Are lymphadenectomy and umbilectomy necessary? med sci monit int med J exp clin res","volume":"26","author":"Jia","year":"2020","journal-title":"22 sept"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1102\u22127","DOI":"10.1016\/j.juro.2012.06.020","article-title":"The clinical epidemiology of urachal carcinoma: results of a large, population based study","volume":"188","author":"Bruins","year":"2012","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2434\u221240","DOI":"10.1002\/cncr.23070","article-title":"Predictors of survival from urachal cancer: a Mayo clinic study of 49 cases","volume":"110","author":"Molina","year":"2007","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1295\u22128","DOI":"10.1097\/01.ju.0000054646.49381.01","article-title":"Multimodality management of urachal carcinoma: the m. d. Anderson cancer center experience","volume":"169","author":"Siefker-Radtke","year":"2003","journal-title":"J Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"388\u221298","DOI":"10.1016\/j.urolonc.2016.04.012","article-title":"Clinical, prognostic, and therapeutic aspects of urachal carcinoma-a comprehensive review with meta-analysis of 1,010 cases","volume":"34","author":"Szarvas","year":"2016","journal-title":"Urol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.07.021","article-title":"Malignant urachal neoplasms: A population-based study and systematic review of literature","volume":"35","author":"Mylonas","year":"2017","journal-title":"Urol Oncol janv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"165.e9","DOI":"10.1016\/j.urolonc.2021.09.008","article-title":"Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma","volume":"40","author":"Flammia","year":"2022","journal-title":"Urol Oncol avr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1808\u221214","DOI":"10.1016\/j.humpath.2015.07.021","article-title":"Urachal carcinoma: a pathologic and clinical study of 46 cases","volume":"46","author":"Dhillon","year":"2015","journal-title":"Hum Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci Basel Switz 13 mars"},{"key":"B24","doi-asserted-by":"publisher","first-page":"341\u22129","DOI":"10.3233\/BLC-160047","article-title":"Obesity and outcomes in patients with metastatic urothelial carcinoma","volume":"2","author":"Leiter","year":"2016","journal-title":"Bladder Cancer Amst Neth"},{"key":"B25","doi-asserted-by":"publisher","first-page":"358\u221262","DOI":"10.1097\/01.pai.0000136552.44045.0f","article-title":"Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder","volume":"13","author":"Raspollini","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1018\u221225","DOI":"10.1097\/MNM.0b013e32834bbd22","article-title":"The clinical value of fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography in postoperative patients with gastrointestinal mucinous adenocarcinoma","volume":"32","author":"Yang","year":"2011","journal-title":"Nucl Med Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"59\u221266","DOI":"10.1080\/2090598X.2020.1858012","article-title":"Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review","volume":"19","author":"Aydh","year":"2020","journal-title":"Arab J Urol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3101\u221212","DOI":"10.1007\/s00330-019-06524-x","article-title":"Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis","volume":"30","author":"van \u2018t Sant","year":"2020","journal-title":"Eur Radiol"},{"key":"B29","first-page":"966\u22129","article-title":"[Clinical analysis of 14 cases of urachal carcinoma]","volume":"27","author":"Chen","year":"2008","journal-title":"Ai Zheng Aizheng Chin J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1740\u22124","DOI":"10.1016\/j.ejso.2019.03.034","article-title":"Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer","volume":"45","author":"Mertens","year":"2019","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.739134","article-title":"Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9\u221211","DOI":"10.1016\/j.eucr.2014.11.004","article-title":"A case of metastatic urachal carcinoma treated with FOLFIRI (irinotecan and 5-fluorouracil\/leucovorin) plus bevacizumab","volume":"3","author":"Kanamaru","year":"2015","journal-title":"Urol Case Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"771\u22125","DOI":"10.1016\/j.eururo.2016.04.037","article-title":"Urachal carcinoma shares genomic alterations with colorectal carcinoma and may respond to epidermal growth factor inhibition","volume":"70","author":"Collazo-Lorduy","year":"2016","journal-title":"Eur Urol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"33\u22129","DOI":"10.1177\/17246008211017152","article-title":"Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients","volume":"36","author":"Yuan","year":"2021","journal-title":"Int J Biol Markers"},{"key":"B35","doi-asserted-by":"publisher","first-page":"39293\u2212301","DOI":"10.18632\/oncotarget.9828","article-title":"Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance","volume":"7","author":"M\u00f3dos","year":"2016","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","first-page":"655\u221261","DOI":"10.21037\/tau.2016.04.01","article-title":"Genetics and biological markers in urachal cancer","volume":"5","author":"Behrendt","year":"2016","journal-title":"Transl Androl Urol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1764\u221273","DOI":"10.1002\/ijc.31547","article-title":"Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas","volume":"143","author":"Reis","year":"2018","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"327\u221230","DOI":"10.1016\/j.humpath.2013.09.008","article-title":"High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations","volume":"45","author":"Sirintrapun","year":"2014","journal-title":"Hum Pathol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"51\u22129","DOI":"10.1177\/1066896919872535","article-title":"Mutational profile using next-generation sequencing may aid in the diagnosis and treatment of urachal adenocarcinoma","volume":"28","author":"Cornejo","year":"2020","journal-title":"Int J Surg Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1110003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T06:23:03Z","timestamp":1674109383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1110003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":39,"alternative-id":["10.3389\/fonc.2023.1110003"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1110003","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"article-number":"1110003"}}